Home » Newsletters » BioWorld Science

BioWorld Science

June 6, 2000

View Archived Issues

Longer term Panretin therapy improves response rate

Allergan and Xoma expand rBPI ophthalmic program

Abciximab complements PTCA in patients with AMI

Aurora Biosciences to collaborate with Cystic Fibrosis Foundation

Early results from first hemophilia B AAV-mediated gene therapy study

The corticotropin-releasing factor receptor antagonist antalarmin reduces stress in monkeys

Parathyroid hormone-related protein analogue aids in bone healing in rabbits

AxyS continues phase II study of tryptase inhibitor as ulcerative colitis treatment

Abbott submits NDA for novel HIV therapy

Amylin initiates phase I clinical studies for atherosclerosis/restenosis drug

MorphoSys enters HuCAL agreements with Genentech and ProChon Biotech

Combined AT1 blockade/ACE inhibition reduces blood pressure, protects kidney in CALM study

Novel spiroketal-containing macrolide with cytotoxic properties isolated from Micromonospora

Potent, broad-spectrum and orally active MMP inhibitor under evaluation at Ono

First clinical results reported for BMS-214662 at recent cancer meeting

CI-1042 (Onyx-015) extensively covered at ASCO meeting; preclinical and clinical results reported

American Biogenetic Sciences to accelerate ABS-205 development for AD

U.S. Federal Trade Commission clears alliance between Kos and DuPont

Abbott discloses potential new treatments for urinary incontinence and sexual dysfunction

Worldwide approval sought for novel allergy and asthma therapy Xolair

DHFR inhibitors and their use in rheumatic conditions

Synthesis and pharmacological activity of new hypolipidemic agents from Nippon Soda

New Snow Brand compounds inhibit neuronal apoptosis

NeuroSearch presents potent new chloride channel blockers for sickle cell disease

Compositions for radioimmunotherapy and diagnosis of tumors containing new chelating agents

Pyrazolopyridine adenosine antagonists, their activity and use described by Fujisawa

New N-type calcium channel blockers synthesized at Ajinomoto

Akzo Nobel's new thrombin inhibitors presented in patent literature

Major milestones achieved in development of Palatin's LeuTech